All cells in organisms ranging from yeast to humans utilize iron as a cofactor or structural element of proteins that function in diverse and critical cellular functions. However, deregulation of the homeostatic mechanisms regulating iron metabolism resulting in a reduction or excess of iron within the cell or outside of it can have serious effects to the health of cells and the organism. This review provides a brief overview of the molecular and cellular mechanisms regulating iron physiology, including the molecules and processes regulating iron uptake, its storage and utilization, its recycling, and its release from the cell, such that the cellular iron levels are sufficient to meet metabolic demand but below those that cause permanent damage. The major focus of review is on the pathological consequences of dysregulation of these homeostatic mechanisms, focusing on the brain. Current advances on the role of iron accumulation to the pathogenesis of rare neurological disorders caused by genetic mutations as well as to the more prevalent and age-associated neurodegenerative diseases are described.
Impact statement
Brain degenerative disorders, which include some neurodevelopmental disorders and age-associated diseases, cause debilitating neurological deficits and are generally fatal. A large body of emerging evidence indicates that iron accumulation in neurons within specific regions of the brain plays an important role in the pathogenesis of many of these disorders. Iron homeostasis is a highly complex and incompletely understood process involving a large number of regulatory molecules. Our review provides a description of what is known about how iron is obtained by the body and brain and how defects in the homeostatic processes could contribute to the development of brain diseases, focusing on Alzheimer’s disease and Parkinson’s disease as well as four other disorders belonging to a class of inherited conditions referred to as neurodegeneration based on iron accumulation (NBIA) disorders. A description of potential therapeutic approaches being tested for each of these different disorders is provided.
YanatoriIKishiF.DMT1 and iron transport. Free Radic Biol Med2019;
133:55–63
4.
PhilpottCCJadhavS.The ins and outs of iron: escorting iron through the mammalian cytosol. Free Radic Biol Med2019;
133:112–7
5.
GaoGLiJZhangYChangY-Z.Cellular iron metabolism and regulation. Adv Exp Med Biol2019;
1173:21–32
6.
GunshinHMackenzieBBergerUVGunshinYRomeroMFBoronWFNussbergerSGollanJLHedigerMA.Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature1997;
388:482–8
7.
AndrewsNC.The iron transporter DMT1. Int J Biochem Cell Biol1999;
31:991–4
8.
McKieATBarrowDLatunde-DadaGORolfsASagerGMudalyEMudalyMRichardsonCBarlowDBomfordAPetersTJRajaKBShiraliSHedigerMAFarzanehFSimpsonRJ.An iron-regulated ferric reductase associated with the absorption of dietary iron. Science2001;
291:1755–9
9.
WhiteCYuanXSchmidtPJBrescianiESamuelTKCampagnaDHallCBishopKCalicchioMLLapierreAWardDMLiuPFlemingMDHamzaI.HRG1 is essential for heme transport from the phagolysosome of macrophages during erythrophagocytosis. Cell Metab2013;
17:261–70
10.
ArosioPIngrassiaRCavadiniP.Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta2009;
1790:589–99
11.
HarrisonPMArosioP.The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta1996;
1275:161–203
12.
KnutsonMD.Iron transport proteins: gateways of cellular and systemic iron homeostasis. J Biol Chem2017;
292:12735–43
13.
ThirupathiAChangY-Z.Brain iron metabolism and CNS diseases. Adv Exp Med Biol2019;
1173:1–19
14.
McKieATMarcianiPRolfsABrennanKWehrKBarrowDMiretSBomfordAPetersTJFarzanehFHedigerMAHentzeMWSimpsonRJ.A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell2000;
5:299–309
15.
DonovanABrownlieAZhouYShepardJPrattSJMoynihanJPawBHDrejerABarutBZapataALawTCBrugnaraCLuxSEPinkusGSPinkusJLKingsleyPDPalisJFlemingMDAndrewsNCZonLI.Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature2000;
403:776–81
16.
VulpeCDKuoYMMurphyTLCowleyLAskwithCLibinaNGitschierJAndersonGJ.Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet1999;
21:195–9
GinzburgYZ.Hepcidin-ferroportin axis in health and disease. Vitam Horm2019;
110:17–45
19.
MusciGPolticelliFBdi PattiMC.Ceruloplasmin-ferroportin system of iron traffic in vertebrates. World J Biol Chem2014;
5:204–15
20.
HellmanNEGitlinJD.Ceruloplasmin metabolism and function. Annu Rev Nutr2002;
22:439–58
21.
GawareVKotadeKDhamakKSomawanshiS.Ceruloplasmin its role and significance: a review. Int J Biomed Res2010;
1:153–62
22.
ShawGCCopeJJLiLCorsonKHerseyCAckermannGEGwynnBLambertAJWingertRATraverDTredeNSBarutBAZhouYMinetEDonovanABrownlieABalzanRWeissMJPetersLLKaplanJZonLIPawBH.Mitoferrin is essential for erythroid iron assimilation. Nature2006;
440:96–100
23.
RichardsonDRLaneDJRBeckerEMHuangML-HWhitnallMSuryo RahmantoYSheftelADPonkaP.Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci U S A2010;
107:10775–82
24.
DrakesmithHNemethEGanzT.Ironing out ferroportin. Cell Metab2015;
22:777–87
25.
De DomenicoIWardDMdi PattiMCBJeongSYDavidSMusciGKaplanJ.Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J2007;
26:2823–31
26.
PatelBNDunnRJDavidS.Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J Biol Chem2000;
275:4305–10
27.
FortnaRRWatsonHANyquistSE.Glycosyl phosphatidylinositol-anchored ceruloplasmin is expressed by rat sertoli cells and is concentrated in detergent-insoluble membrane fractions. Biol Reprod1999;
61:1042–9
28.
ConradMECrosbyWH.Intestinal mucosal mechanisms controlling iron absorption. Blood1963;
22:406–15
29.
CmejlaRPetrakJCmejlovaJ.A novel iron responsive element in the 3’UTR of human MRCKalpha. Biochem Biophys Res Commun2006;
341:158–66
30.
CmejlaRPtackovaPPetrakJSavvulidiFCernyJSebestaOVyoralD.Human MRCKalpha is regulated by cellular iron levels and interferes with transferrin iron uptake. Biochem Biophys Res Commun2010;
395:163–7
31.
DuFQianCQianZMWuX-MXieHYungW-HKeY.Hepcidin directly inhibits transferrin receptor 1 expression in astrocytes via a cyclic AMP-protein kinase a pathway. Glia2011;
59:936–45
32.
De DomenicoIWardDMLangelierCVaughnMBNemethESundquistWIGanzTMusciGKaplanJ.The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell2007;
18:2569–78
33.
Wessling-ResnickM.Iron homeostasis and the inflammatory response. Annu Rev Nutr2010;
30:105–22
34.
GanzTNemethE.Hepcidin and iron homeostasis. Biochim Biophys Acta2012;
1823:1434–43
35.
MuckenthalerMUGalyBHentzeMW.Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr2008;
28:197–213
36.
AndersonCPShenMEisensteinRSLeiboldEA.Mammalian iron metabolism and its control by iron regulatory proteins. Biochim Biophys Acta2012;
1823:1468–83
37.
WangJPantopoulosK.Regulation of cellular iron metabolism. Biochem J2011;
434:365–81
38.
ZhouZDTanE-K.Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases. Mol Neurodegener2017;
21
39.
GammellaEBurattiPCairoGRecalcatiS.Macrophages: central regulators of iron balance. Metallomics2014;
6:1336–45
40.
HidalgoCNúñezMT.Calcium, iron and neuronal function. IUBMB Life2007;
59:280–5
41.
HidalgoCCarrascoMAMuñozPNúñezMT.A role for reactive oxygen/nitrogen species and iron on neuronal synaptic plasticity. Antioxid Redox Signal2007;
9:245–55
42.
SalvadorGA.Iron in neuronal function and dysfunction. Biofactors2010;
36:103–10
43.
CodazziFPelizzoniIZacchettiDGrohovazF.Iron entry in neurons and astrocytes: a link with synaptic activity. Front Mol Neurosci2015;
8:18
44.
MuñozPHumeresA.Iron deficiency on neuronal function. Biometals2012;
25:825–35
45.
StephensonENathooNMahjoubYDunnJFYongVW.Iron in multiple sclerosis: roles in neurodegeneration and repair. Nat Rev Neurol2014;
10:459–68
46.
BallabhPBraunANedergaardM.The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis2004;
16:1–13
47.
DanemanRPratA.The blood-brain barrier. Cold Spring Harb Perspect Biol2015;
7:a020412
48.
PetillonCHergesheimerRPuyHCorciaPVourc’hPAndresCKarimZBlascoH.The relevancy of data regarding the metabolism of iron to our understanding of deregulated mechanisms in ALS; hypotheses and pitfalls. Front Neurosci2018;
12:1031
49.
MasaldanSBushAIDevosDRollandASMoreauC.Striking while the iron is hot: iron metabolism and ferroptosis in neurodegeneration. Free Radic Biol Med2019;
133:221–33
50.
DeGregorio-RocasolanoNMartí-SistacOGasullT.Deciphering the iron side of stroke: neurodegeneration at the crossroads between iron dyshomeostasis, excitotoxicity, and ferroptosis. Front Neurosci2019;
13:85
51.
JeongSYDavidS.Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem2003;
278:27144–8
52.
WuLJLeendersAGMCoopermanSMeyron-HoltzESmithSLandWTsaiRYLBergerUVShengZ-HRouaultTA.Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier. Brain Res2004;
1001:108–17
53.
DescampsLDehouckMPTorpierGCecchelliR.Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am J Physiol1996;
270:H1149–1158
54.
RaubTJNewtonCR.Recycling kinetics and transcytosis of transferrin in primary cultures of bovine brain microvessel endothelial cells. J Cell Physiol1991;
149:141–51
55.
QianZ-MKeY.Brain iron transport. Biol Rev Camb Philos Soc2019;
94:1672–84
56.
QianZ-MChangY-ZZhuLYangLDuJ-RHoK-PWangQLiL-ZWangC-YGeXJingNLLiLKeY.Development and iron-dependent expression of hephaestin in different brain regions of rats. J Cell Biochem2007;
102:1225–33
57.
RouaultTAZhangD-LJeongSY.Brain iron homeostasis, the choroid plexus, and localization of iron transport proteins. Metab Brain Dis2009;
24:673–84
58.
McCarthyRCKosmanDJ.Mechanisms and regulation of iron trafficking across the capillary endothelial cells of the blood-brain barrier. Front Mol Neurosci2015;
8:31
59.
MaleckiEADevenyiAGBeardJLConnorJR.Existing and emerging mechanisms for transport of iron and manganese to the brain. J Neurosci Res1999;
56:113–22
60.
MoosTRosengren NielsenTSkjørringeTMorganEH.Iron trafficking inside the brain. J Neurochem2007;
103:1730–40
61.
ConnorJRBoeshoreKLBenkovicSAMenziesSL.Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res1994;
37:461–5
62.
HanJDayJRConnorJRBeardJL.H and L ferritin subunit mRNA expression differs in brains of control and iron-deficient rats. J Nutr2002;
132:2769–74
63.
CheepsunthornPPalmerCConnorJR.Cellular distribution of ferritin subunits in postnatal rat brain. J Comp Neurol1998;
400:73–86
64.
MøllgårdKBalslevY.The subcellular distribution of transferrin in rat choroid plexus studied with immunogold labelling of ultracryosections. Histochem J1989;
21:441–8
65.
TsutsumiMSkinnerMKSanders-BushE.Transferrin gene expression and synthesis by cultured choroid plexus epithelial cells. Regulation by serotonin and cyclic adenosine 3’,5’-monophosphate. J Biol Chem1989;
264:9626–31
66.
de Arriba ZerpaGASalehMCFernándezPMGuillouFEspinosa de los MonterosAde VellisJZakinMMBaronB.Alternative splicing prevents transferrin secretion during differentiation of a human oligodendrocyte cell line. J Neurosci Res2000;
61:388–95
67.
DuchangeNSalehM-Cde Arriba ZerpaGPidouxJGuillouFZakinMMBaronB.Alternative splicing in the brain of mice and rats generates transferrin transcripts lacking, as in humans, the signal peptide sequence. Neurochem Res2002;
27:1459–63
68.
BradburyMW.Transport of iron in the blood-brain-cerebrospinal fluid system. J Neurochem1997;
69:443–54
69.
MoosTMorganEH.Evidence for low molecular weight, non-transferrin-bound iron in rat brain and cerebrospinal fluid. J Neurosci Res1998;
54:486–94
70.
TripathiAKHaldarSQianJBeserraASudaSSinghAHopferUChenSGGarrickMDTurnerJRKnutsonMDSinghN.Prion protein functions as a ferrireductase partner for ZIP14 and DMT1. Free Radic Biol Med2015;
84:322–30
71.
HaldarSTripathiAQianJBeserraASudaSMcElweeMTurnerJHopferUSinghN.Prion protein promotes kidney iron uptake via its ferrireductase activity. J Biol Chem2015;
290:5512–22
72.
SinghNAsthanaABaksiSDesaiVHaldarSHariSTripathiAK.The prion-ZIP connection: from cousins to partners in iron uptake. Prion2015;
9:420–8
73.
SinghAHaldarSHorbackKTomCZhouLMeyersonHSinghN.Prion protein regulates iron transport by functioning as a ferrireductase. J Alzheimers Dis2013;
35:541–52
74.
BrownDR.α-Synuclein as a ferrireductase. Biochem Soc Trans2013;
41:1513–7
75.
DaviesPMouallaDBrownDR.Alpha-synuclein is a cellular ferrireductase. PLoS ONE2011;
6:e15814
76.
McDowallJSBrownDR.Alpha-synuclein: relating metals to structure, function and inhibition. Metallomics2016;
8:385–97
77.
McDowallJSNtaiIHoneychurchKCHartJPColinPSchneiderBLBrownDR.Alpha-synuclein ferrireductase activity is detectible in vivo, is altered in Parkinson’s disease and increases the neurotoxicity of DOPAL. Mol Cell Neurosci2017;
85:1–11
78.
RathnasamyGLingE-AKaurC.Consequences of iron accumulation in microglia and its implications in neuropathological conditions. CNS Neurol Disord Drug Targets2013;
12:785–98
79.
WardRJCrichtonRRTaylorDLDella CorteLSraiSKDexterDT.Iron and the immune system. J Neural Transm2011;
118:315–28
80.
BrockJH.Lactoferrin-50 years on. Biochem Cell Biol2012;
90:245–51
81.
JiangHSongNJiaoQShiLDuX.Iron pathophysiology in Parkinson diseases. Adv Exp Med Biol2019;
1173:45–66
82.
BonnD.Pumping iron in Parkinson’s disease. Lancet1996;
347:1614
83.
FaucheuxBANillesseNDamierPSpikGMouatt-PrigentAPierceALeveugleBKubisNHauwJJAgidY.Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci U S A1995;
92:9603–7
84.
JiCKosmanDJ.Molecular mechanisms of non-transferrin-bound and transferring-bound iron uptake in primary hippocampal neurons. J Neurochem2015;
133:668–83
85.
SterlingJGutthaSSongYSongDHadziahmetovicMDunaiefJL.Iron importers Zip8 and Zip14 are expressed in retina and regulated by retinal iron levels. Exp Eye Res2017;
155:15–23
86.
BaumannBSterlingJSongYSongDFruttigerMGilliesMShenWDunaiefJL.Conditional Müller cell ablation leads to retinal iron accumulation. Invest Ophthalmol Vis Sci2017;
58:4223–34
87.
WongBXTsatsanisALimLQAdlardPABushAIDuceJA.β-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS One2014;
9:e114174
88.
HoepkenHHKortenTRobinsonSRDringenR.Iron accumulation, iron-mediated toxicity and altered levels of ferritin and transferrin receptor in cultured astrocytes during incubation with ferric ammonium citrate. J Neurochem2004;
88:1194–202
89.
ZarrukJGBerardJLPassos dos SantosRKronerALeeJArosioPDavidS.Expression of iron homeostasis proteins in the spinal cord in experimental autoimmune encephalomyelitis and their implications for iron accumulation. Neurobiol Dis2015;
81:93–107
90.
QianZMToYTangPLFengYM.Transferrin receptors on the plasma membrane of cultured rat astrocytes. Exp Brain Res1999;
129:473–6
91.
QianZMLiaoQKToYKeYTsoiYKWangGFHoKP.Transferrin-bound and transferrin free iron uptake by cultured rat astrocytes. Cell Mol Biol2000;
46:541–8
92.
HuangSDuFLiLLiuYLiuYZhangCQianZM.Angiotensin II inhibits uptake of transferrin-bound iron but not non-transferrin-bound iron by cultured astrocytes. Neuropeptides2014;
48:161–6
93.
BurdoJRMenziesSLSimpsonIAGarrickLMGarrickMDDolanKGHaileDJBeardJLConnorJR.Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J Neurosci Res2001;
66:1198–207
94.
TulpuleKRobinsonSRBishopGMDringenR.Uptake of ferrous iron by cultured rat astrocytes. J Neurosci Res2010;
88:563–71
95.
SongNJiangHWangJXieJ-X.Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx. J Neurosci Res2007;
85:3118–26
96.
BishopGMScheiberIFDringenRRobinsonSR.Synergistic accumulation of iron and zinc by cultured astrocytes. J Neural Transm2010;
117:809–17
97.
PelizzoniIZacchettiDCampanellaAGrohovazFCodazziF.Iron uptake in quiescent and inflammation-activated astrocytes: a potentially neuroprotective control of iron burden. Biochim Biophys Acta2013;
1832:1326–33
98.
TodorichBZhangXConnorJR.H-ferritin is the major source of iron for oligodendrocytes. Glia2011;
59:927–35
99.
TodorichBZhangXSlagle-WebbBSeamanWEConnorJR.Tim-2 is the receptor for H-ferritin on oligodendrocytes. J Neurochem2008;
107:1495–505
100.
HanJSeamanWEDiXWangWWillinghamMTortiFMTortiSV.Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells. PLoS One2011;
6:e23800
101.
SchulzKVulpeCDHarrisLZDavidS.Iron efflux from oligodendrocytes is differentially regulated in gray and white matter. J Neurosci2011;
31:13301–11
102.
KoeppenAH.A brief history of brain iron research.J Neurol Sci. 2003;
207:95–7.
103.
PirpamerLHoferEGesierichBDe GuioFFreudenbergerPSeilerSDueringMJouventEDuchesnayEDichgansMRopeleSSchmidtR.Determinants of iron accumulation in the normal aging brain. Neurobiol Aging2016;
43:149–55
104.
ZeccaLGalloriniMSchünemannVTrautweinAXGerlachMRiedererPVezzoniPTampelliniD.Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem2001;
76:1766–73
105.
ZeccaLYoudimMBHRiedererPConnorJRCrichtonRR.Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci2004;
5:863–73
106.
CrichtonRRDexterDTWardRJ.Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm2011;
118:301–14
107.
ConnorJRMenziesSLSt MartinSMMufsonEJ.Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J Neurosci Res1990;
27:595–611
108.
LiK.Iron pathophysiology in Friedreich’s ataxia. Adv Exp Med Biol2019;
1173:125–43
109.
WangTXuS-FFanY-GLiL-BGuoC.Iron pathophysiology in Alzheimer’s diseases. Adv Exp Med Biol2019;
1173:67–104
110.
AlmutairiMMAXuGShiH.Iron pathophysiology in stroke. Adv Exp Med Biol2019;
1173:105–23
111.
ZhaoZ.Iron and oxidizing species in oxidative stress and Alzheimer’s disease. Aging Med2019;
2:82–7
112.
KotzbauerPTTruaxACTrojanowskiJQLeeVM-Y.Altered neuronal mitochondrial coenzyme a synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci2005;
25:689–98
113.
JoppeKRoserA-EMaassFLingorP.The contribution of iron to protein aggregation disorders in the Central nervous system. Front Neurosci2019;
13:15
114.
StockwellBRFriedmann AngeliJPBayirHBushAIConradMDixonSJFuldaSGascónSHatziosSKKaganVENoelKJiangXLinkermannAMurphyMEOverholtzerMOyagiAPagnussatGCParkJRanQRosenfeldCSSalnikowKTangDTortiSMTortiSVToyokuniSWoerpelKAZhangDD.Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease.Cell2017;
171:273–85
115.
MuhoberacBBVidalR.Iron, ferritin, hereditary ferritinopathy, and neurodegeneration. Front Neurosci2019;
13:1195
116.
GuineySJAdlardPABushAIFinkelsteinDIAytonS.Ferroptosis and cell death mechanisms in Parkinson’s disease. Neurochem Int2017;
104:34–48
117.
Paisán-RuizCLiASchneiderSAHoltonJLJohnsonRKiddDChatawayJBhatiaKPLeesAJHardyJReveszTHouldenH.Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging2012;
33:814–23
118.
RatanRR.The chemical biology of ferroptosis in the central nervous system. Cell Chem Biol2020;
27:479–98
119.
WuJ-RTuoQ-ZLeiP.Ferroptosis, a recent defined form of critical cell death in neurological disorders. J Mol Neurosci2018;
66:197–206
120.
DollSFreitasFPShahRAldrovandiMda SilvaMCIngoldIGrocinAGXavier da SilvaTNPanziliusEScheelCHMourãoABudayKSatoMWanningerJVignaneTMohanaVRehbergMFlatleyASchepersAKurzAWhiteDSauerMSattlerMTateEWSchmitzWSchulzeAO'DonnellVPronethBPopowiczGMPrattDAAngeliJPFConradM.FSP1 is a glutathione-independent ferroptosis suppressor. Nature2019;
575:693–8
121.
HuangXTLiuXYeCYTaoLXZhouHZhangHY.Iron-induced energy supply deficiency and mitochondrial fragmentation in neurons. J Neurochem2018;
147:816–30
122.
RakshitJMallickARoySSarbajnaADuttaMBandyopadhyayJ.Iron-Induced apoptotic cell death and autophagy dysfunction in human neuroblastoma cell line SH-SY5Y. Biol Trace Elem Res2020;
193:138–51
123.
YuanYXuFCaoYXuLYuCYangFZhangPWangLShenGWangJXuY.Iron accumulation leads to bone loss by inducing mesenchymal stem cell apoptosis through the activation of Caspase3. Biol Trace Elem Res2019;
187:434–41
124.
de MajoMKoontzMRowitchDUllianEM.An update on human astrocytes and their role in development and disease. Glia2020;
68:685–704
125.
Sidoryk-WęgrzynowiczMStrużyńskaL.Astroglial contribution to tau-dependent neurodegeneration. Biochem J2019;
476:3493–504
126.
ValoriCFGuidottiGBrambillaLRossiD.Astrocytes in motor neuron diseases. Adv Exp Med Biol2019;
1175:227–72
127.
GrayM.Astrocytes in Huntington’s disease. Adv Exp Med Biol2019;
1175:355–81
128.
CheliVTSantiago GonzálezDAMarzialiLNZamoraNNGuitartMESpreuerVPasquiniJMPaezPM.The divalent metal transporter 1 (DMT1) is required for iron uptake and normal development of oligodendrocyte progenitor cells. J Neurosci2018;
38:9142–59
129.
NasrabadySERizviBGoldmanJEBrickmanAM.White matter changes in Alzheimer’s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun2018;
6:22
130.
CaiZXiaoM.Oligodendrocytes and Alzheimer’s disease. Int J Neurosci2016;
126:97–104
131.
LoPrestiP.Tau in oligodendrocytes takes neurons in sickness and in health. Int J Mol Sci2018;
19:2408
132.
FerrerI.Oligodendrogliopathy in neurodegenerative diseases with abnormal protein aggregates: the forgotten partner. Prog Neurobiol2018;
169:24–54
133.
HametnerSWimmerIHaiderLPfeifenbringSBrückWLassmannH.Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol2013;
74:848–61
134.
BartzokisG.Age-related myelin breakdown: a developmental model of cognitive decline and alzheimer’s disease. Neurobiol Aging2004;
25:5–18; author reply: 49–62
135.
BartzokisG.Alzheimer’s disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging2011;
32:1341–71
136.
BartzokisGLuPHTishlerTAFongSMOluwadaraBFinnJPHuangDBordelonYMintzJPerlmanS.Myelin Breakdown and iron changes in Huntington’s disease: pathogenesis and treatment implications. Neurochem Res2007;
32:1655–64
137.
BinolfiARasiaRMBertonciniCWCeolinMZweckstetterMGriesingerCJovinTMFernándezCO.Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc2006;
128:9893–901
138.
BartelsMWeckbeckerDKuhnP-HRyazanovSLeonovAGriesingerCLichtenthalerSFBötzelKGieseA.Iron-mediated aggregation and toxicity in a novel neuronal cell culture model with inducible alpha-synuclein expression. Sci Rep2019;
9:9100
139.
ChiotALobsigerCSBoilléeS.New insights on the disease contribution of neuroinflammation in amyotrophic lateral sclerosis. Curr Opin Neurol2019;
32:764–70
FrostGRJonasLALiY-M.Friend, foe or both? Immune activity in Alzheimer’s disease. Front Aging Neurosci2019;
11:337
142.
LiXLiuYZhengQYaoGChengPBuGXuHZhangY.Ferritin light chain interacts with PEN-2 and affects γ-secretase activity. Neurosci Lett2013;
548:90–4
143.
FahnS.The 200-year journey of Parkinson disease: reflecting on the past and looking towards the future. Parkinsonism Relat Disord2018;
46(Suppl 1):S1–5
144.
MaetzlerWBergD.Parkinson disease in 2017: changing views after 200 years of Parkinson disease. Nat Rev Neurol2018;
14:70–2
145.
McDonaldCGordonGHandAWalkerRWFisherJM.200 Years of Parkinson’s disease: what have we learnt from James Parkinson?Age Age2018;
47:209–14
FangCLvLMaoSDongHLiuB.Cognition deficits in Parkinson’s disease: mechanisms and treatment. Parkinsons Dis2020;
2020:2076942
148.
GoldmanJGSiegE.Cognitive impairment and dementia in Parkinson disease. Clin Geriatr Med2020;
36:365–77
149.
JellingerKPaulusWGrundke-IqbalIRiedererPYoudimMB.Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases. J Neural Transm Park Dis Dement Sect1990;
2:327–40
150.
KaurDAndersenJ.Does cellular iron dysregulation play a causative role in Parkinson’s disease?Ageing Res Rev2004;
3:327–43
151.
ShenXMDryhurstG.Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity. Chem Res Toxicol1998;
11:824–37
152.
ShenXMZhangFDryhurstG.Oxidation of dopamine in the presence of cysteine: characterization of new toxic products. Chem Res Toxicol1997;
10:147–55
153.
GerlachMDoubleKRiedererPHirschEJellingerKJennerPTrautweinAYoudimMB.Iron in the parkinsonian substantia nigra. Mov Disord1997;
12:258–60
154.
DoubleKLGerlachMSchünemannVTrautweinAXZeccaLGalloriniMYoudimMBHRiedererPBen-ShacharD.Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol2003;
66:489–94
155.
GerlachMDoubleKLBen-ShacharDZeccaLYoudimMBHRiedererP.Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson’s disease. Neurotox Res2003;
5:35–44
156.
XingYSapuanADineenRAAuerDP.Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI. Mov Disord2018;
33:1792–9
157.
ZuccaFASegura-AguilarJFerrariEMuñozPParisISulzerDSarnaTCasellaLZeccaL.Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson’s disease. Prog Neurobiol2017;
155:96–119
158.
YoudimMBBen-ShacharDRiedererP.The enigma of neuromelanin in Parkinson’s disease substantia nigra. J Neural Transm Suppl1994;
43:113–22
159.
JellingerKAKienzlERumpelmaierGPaulusWRiedererPStachelbergerHYoudimMBBen-ShacharD.Iron and ferritin in substantia nigra in Parkinson’s disease. Adv Neurol1993;
60:267–72
160.
FaucheuxBAMartinM-EBeaumontCHauwJ-JAgidYHirschEC.Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson’s disease. J Neurochem2003;
86:1142–8
161.
ThomsenMSAndersenMVChristoffersenPRJensenMDLichotaJMoosT.Neurodegeneration with inflammation is accompanied by accumulation of iron and ferritin in microglia and neurons. Neurobiol Dis2015;
81:108–18
162.
RochaEMDe MirandaBSandersLH.Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiol Dis2018;
109:249–57
163.
GeldersGBaekelandtVVan der PerrenA.Linking neuroinflammation and neurodegeneration in Parkinson’s disease. J Immunol Res2018;
2018:4784268
164.
CabezudoDBaekelandtVLobbestaelE.Multiple-Hit hypothesis in Parkinson’s disease: LRRK2 and inflammation. Front Neurosci2020;
14:376
165.
BlesaJPhaniSJackson-LewisVPrzedborskiS.Classic and new animal models of Parkinson’s disease. J Biomed Biotechnol2012;
2012:845618
166.
GubelliniPKachidianP.Animal models of Parkinson’s disease: an updated overview. Rev Neurol2015;
171:750–61
167.
SchoberA.Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res2004;
318:215–24
168.
OiwaYEberlingJLNagyDPivirottoPEmborgMEBankiewiczKS.Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Front Biosci2003;
8:a155–166
Bandres-CigaSDiez-FairenMKimJJSingletonAB.Genetics of Parkinson’s disease: an introspection of its journey towards precision medicine. Neurobiol Dis2020;
137:104782
171.
SingletonABFarrerMJohnsonJSingletonAHagueSKachergusJHulihanMPeuralinnaTDutraANussbaumRLincolnSCrawleyAHansonMMaraganoreDAdlerCCooksonMRMuenterMBaptistaMMillerDBlancatoJHardyJ,
Gwinn-Hardy K. alpha-synuclein locus triplication causes Parkinson’s disease. Science2003;
302:841
172.
IpCWKlausL-CKarikariAAVisanjiNPBrotchieJMLangAEVolkmannJKoprichJB.AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease. Acta Neuropathol Commun2017;
5:11
173.
KoprichJBJohnstonTHReyesGOmanaVBrotchieJM.Towards a non-human primate model of alpha-synucleinopathy for development of therapeutics for Parkinson’s disease: optimization of AAV1/2 delivery parameters to drive sustained expression of alpha synuclein and dopaminergic degeneration in macaque. PLoS One2016;
11:e0167235
174.
Van der PerrenACasteelsCVan LaereKGijsbersRVan den HauteCBaekelandtV.Development of an alpha-synuclein based rat model for Parkinson’s disease via stereotactic injection of a recombinant adeno-associated viral vector. J Vis Exp2016;
108:53670
175.
LandeckNBuckKKirikD.Toxic effects of human and rodent variants of alpha-synuclein in vivo. Eur J Neurosci2017;
45:536–47
176.
FieldsCRBengoa-VergnioryNWade-MartinsR.Targeting alpha-synuclein as a therapy for Parkinson’s disease. Front Mol Neurosci2019;
12:299
177.
ZengX-SGengW-SJiaJ-JChenLZhangP-P.Cellular and molecular basis of neurodegeneration in Parkinson disease. Front Aging Neurosci2018;
10:109
178.
KordowerJHChuYHauserRAFreemanTBOlanowCW.Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med2008;
14:504–6
179.
MaJGaoJWangJXieA.Prion-Like mechanisms in Parkinson’sdisease. Front Neurosci2019;
13:552
180.
Sian-HülsmannJMandelSYoudimMBHRiedererP.The relevance of iron in the pathogenesis of Parkinson’s disease. J Neurochem2011;
118:939–57
181.
DexterDTWellsFRAgidFAgidYLeesAJJennerPMarsdenCD.Increased nigral iron content in postmortem parkinsonian brain. Lancet1987;
2:1219–20
182.
GötzMEDoubleKGerlachMYoudimMBHRiedererP.The relevance of iron in the pathogenesis of Parkinson’s disease. Ann N Y Acad Sci2004;
1012:193–208
183.
GenoudSSeniorAMHareDJDoubleKL.Meta-analysis of copper and iron in Parkinson’s disease brain and biofluids. Mov Disord2019;
35:662–71
184.
WolozinBGoltsN.Iron and Parkinson’s disease. Neuroscientist2002;
8:22–32
GoltsNSnyderHFrasierMTheislerCChoiPWolozinB.Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J Biol Chem2002;
277:16116–23
187.
UverskyVNLiJFinkAL.Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure. J Biol Chem2001;
276:44284–96
188.
LvZJiangHXuHSongNXieJ.Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson’s disease. J Neural Transm2011;
118:361–9
189.
SoficEPaulusWJellingerKRiedererPYoudimMB.Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem1991;
56:978–82
190.
RiedererPDirrAGoetzMSoficEJellingerKYoudimMB.Distribution of iron in different brain regions and subcellular compartments in Parkinson’s disease. Ann Neurol1992;
32(Suppl):S101–104
191.
UchidaYKanHSakuraiKAraiNKatoDKawashimaSUekiYMatsukawaN.Voxel-based quantitative susceptibility mapping in Parkinson’s disease with mild cognitive impairment. Mov Disord2019;
34:1164–73
192.
TambascoNPaolini PaolettiFChiappinielloALisettiVNigroPEusebiPChiariniPRomoliMBrahimiESimoniSFilideiMFloridiPTarducciRParnettiLCalabresiP.T2*-weighted MRI values correlate with motor and cognitive dysfunction in Parkinson’s disease. Neurobiol Aging2019;
80:91–8
193.
MochizukiHChoongC-JBabaK.Parkinson’s disease and iron. J Neural Transm2020;
127:181–7
194.
SengstockGJOlanowCWMenziesRADunnAJArendashGW.Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res1993;
35:67–82
195.
SzirákiIMohanakumarKPRauhalaPKimHGYehKJChiuehCC.Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. Neuroscience1998;
85:1101–11
196.
WesemannWBlaschkeSSolbachMGroteCClementHWRiedererP.Intranigral injected iron progressively reduces striatal dopamine metabolism. J Neural Transm Park Dis Dement Sect1994;
8:209–14
197.
Ben-ShacharDYoudimMB.Intranigral iron injection induces behavioral and biochemical “parkinsonism” in rats. J Neurochem1991;
57:2133–5
198.
LanJJiangDH.Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm1997;
104:469–81
199.
KaurDYantiriFRajagopalanSKumarJMoJQBoonplueangRViswanathVJacobsRYangLBealMFDiMonteDVolitaskisIEllerbyLChernyRABushAIAndersenJK.Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron2003;
37:899–909
200.
MochizukiHImaiHEndoKYokomizoKMurataYHattoriNMizunoY.Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci Lett1994;
168:251–3
201.
WangJXuH-MYangH-DDuX-XJiangHXieJ-X.Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins. Neurochem Int2009;
54:43–8
202.
WangJJiangHXieJ-X.Time dependent effects of 6-OHDA lesions on iron level and neuronal loss in rat nigrostriatal system. Neurochem Res2004;
29:2239–43
203.
HeYLeeTLeongSK.Time course of dopaminergic cell death and changes in iron, ferritin and transferrin levels in the rat substantia nigra after 6-hydroxydopamine (6-OHDA) lesioning. Free Radic Res1999;
31:103–12
204.
GuoCHaoL-JYangZ-HChaiRZhangSGuYGaoH-LZhongM-LWangTLiJ-YWangZ-Y.Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice. Exp Neurol2016;
280:13–23
205.
GotoKMochizukiHImaiHAkiyamaHMizunoY.An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Brain Res1996;
724:125–8
206.
UittiRJRajputAHRozdilskyBBickisMWollinTYuenWK.Regional metal concentrations in Parkinson’s disease, other chronic neurological diseases, and control brains. Can J Neurol Sci1989;
16:310–4
207.
HeYThongPSLeeTLeongSKMaoBYDongFWattF.Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic Biol Med2003;
35:540–7
208.
DoubleKLGerlachMYoudimMBRiedererP.Impaired iron homeostasis in Parkinson’s disease. J Neural Transm Suppl2000;
60:37–58
209.
BergDGerlachMYoudimMBDoubleKLZeccaLRiedererPBeckerG.Brain iron pathways and their relevance to Parkinson’s disease. J Neurochem2001;
79:225–36
210.
HirschEC.Altered regulation of iron transport and storage in Parkinson’s disease. J Neural Transm Suppl2006;
71:201–4
211.
XuanMGuanXGuQShenZYuXQiuTLuoXSongRJiaerkenYXuXHuangPLuoWZhangM.Different iron deposition patterns in early- and middle-late-onset Parkinson’s disease. Parkinsonism Relat Disord2017;
44:23–7
212.
HuangYCheungLRoweDHallidayG.Genetic contributions to Parkinson’s disease. Brain Res Brain Res Rev2004;
46:44–70
213.
WangJJiangHXieJ-X.Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur J Neurosci2007;
25:2766–72
214.
DaviesKMBohicSCarmonaAOrtegaRCottamVHareDJFinbergJPMReyesSHallidayGMMercerJFBDoubleKL.Copper pathology in vulnerable brain regions in Parkinson’s disease. Neurobiol Aging2014;
35:858–66
215.
ZhangZHouLSongJ-LSongNSunY-JLinXWangX-LZhangF-ZGeY-L.Pro-inflammatory cytokine-mediated ferroportin down-regulation contributes to the nigral iron accumulation in lipopolysaccharide-induced parkinsonian models. Neuroscience2014;
257:20–30
216.
SongNWangJJiangHXieJ.Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson’s disease. Free Radic Biol Med2010;
48:332–41
217.
KalivendiSVKotamrajuSCunninghamSShangTHillardCJKalyanaramanB.1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide. Biochem J2003;
371:151–64
218.
JiangHSongNXuHZhangSWangJXieJ.Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent. Cell Res2010;
20:345–56
219.
SalazarJMenaNHunotSPrigentAAlvarez-FischerDArredondoMDuyckaertsCSazdovitchVZhaoLGarrickLMNuñezMTGarrickMDRaisman-VozariRHirschEC.Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson’s disease. Proc Natl Acad Sci U S A2008;
105:18578–83
220.
ZhangSWangJSongNXieJJiangH.Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. Neurobiol Aging2009;
30:1466–76
221.
HowittJGysbersAMAytonSCarew-JonesFPutzUFinkelsteinDIHallidayGMTanS-S.Increased Ndfip1 in the substantia nigra of parkinsonian brains is associated with elevated iron levels. PLoS One2014;
9:e87119
222.
FillebeenCMitchellVDexterDBenaissaMBeauvillainJSpikGPierceA.Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment. Brain Res Mol Brain Res1999;
72:183–94
223.
FillebeenCRuchouxMMMitchellVVincentSBenaïssaMPierceA.Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. Brain Res Mol Brain Res2001;
96:103–13
224.
ConnorJRSnyderBSArosioPLoefflerDALeWittP.A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer’s diseased brains. J Neurochem1995;
65:717–24
225.
FaucheuxBAMartinM-EBeaumontCHunotSHauwJ-JAgidYHirschEC.Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson’s disease. J Neurochem2002;
83:320–30
226.
DexterDTCarayonAJavoy-AgidFAgidYWellsFRDanielSELeesAJJennerPMarsdenCD.Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain1991;
114:1953–75
227.
DexterDTCarayonAVidailhetMRubergMAgidFAgidYLeesAJWellsFRJennerPMarsdenCD.Decreased ferritin levels in brain in Parkinson’s disease. J Neurochem1990;
55:16–20
228.
KawabataH.Transferrin and transferrin receptors update. Free Radic Biol Med2019;
133:46–54
229.
MastroberardinoPGHoffmanEKHorowitzMPBetarbetRTaylorGChengDNaHMGutekunstC-AGearingMTrojanowskiJQAndersonMChuCTPengJGreenamyreJT.A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson’s disease. Neurobiol Dis2009;
34:417–31
230.
CarrollCBZeisslerM-LChadbornNGibsonKWilliamsGZajicekJPMorrisonKEHanemannCO.Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson’s disease. Neurochem Int2011;
59:73–80
231.
BjørklundGHoferTNurchiVMAasethJ.Iron and other metals in the pathogenesis of Parkinson’s disease: toxic effects and possible detoxification. J Inorg Biochem2019;
199:110717
232.
ChenBWenXJiangHWangJSongNXieJ.Interactions between iron and α-synuclein pathology in Parkinson’s disease. Free Radic Biol Med2019;
141:253–60
233.
NullBIndiSSRaoKSJ.Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study. Neurosci Lett2007;
424:78–82
234.
HeQSongNXuHWangRXieJJiangH.Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells. J Neural Transm2011;
118:397–406
235.
WangRWangYQuLChenBJiangHSongNXieJ.Iron-induced oxidative stress contributes to α-synuclein phosphorylation and up-regulation via polo-like kinase 2 and casein kinase 2. Neurochem Int2019;
125:127–35
236.
LiuBHongJ-S.Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther2003;
304:7
237.
McGeerPLMcGeerEG.Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord2004;
10(Suppl 1):S3–7
238.
ColonnaMButovskyO.Microglia function in the Central nervous system during health and neurodegeneration. Annu Rev Immunol2017;
35:441–68
239.
NnahICWessling-ResnickM.Brain iron homeostasis: a focus on microglial iron. Pharmaceuticals2018;
11:129
240.
UverskyVNYaminGSouillacPOGoersJGlaserCBFinkAL.Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett2002;
517:239–44
ZhouWLongCReaneySHDi MonteDAFinkALUverskyVN.Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim Biophys Acta2010;
1802:322–30
243.
GlaserCBYaminGUverskyVNFinkAL.Methionine oxidation, alpha-synuclein and Parkinson’s disease. Biochim Biophys Acta2005;
1703:157–69
244.
DoubleKLHallidayGM.New face of neuromelanin. J Neural Transm Suppl2006;
70:119–23
245.
FasanoMGiraudoSCohaSBergamascoBLopianoL.Residual substantia nigra neuromelanin in Parkinson’s disease is cross-linked to alpha-synuclein. Neurochem Int2003;
42:603–6
246.
LuYPrudentMFauvetBLashuelHAGiraultHH.Phosphorylation of α-synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-synuclein in the pathogenesis of Parkinson’s disease and related disorders. ACS Chem Neurosci2011;
2:667–75
247.
LiWJiangHSongNXieJ.Oxidative stress partially contributes to iron-induced α-synuclein aggregation in SK-N-SH cells. Neurotox Res2011;
19:435–42
248.
RogersJTMikkilineniSCantuti-CastelvetriISmithDHHuangXBandyopadhyaySCahillCMMaccecchiniMLLahiriDKGreigNH.The alpha-synuclein 5’untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and posiphen. J Neural Transm2011;
118:493–507
249.
XiaoYChenXHuangSLiGMoMZhangLChenCGuoWZhouMWuZCenLLongSLiSYangXQuSPeiZXuP.Iron promotes α-synuclein aggregation and transmission by inhibiting TFEB-mediated autophagosome-lysosome fusion. J Neurochem2018;
145:34–50
250.
BaksiSTripathiAKSinghN.Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: implications for visual manifestations of Parkinson’s disease. Free Radic Biol Med2016;
97:292–306
251.
VargasKJMakaniSDavisTWestphalCHCastilloPEChandraSS.Synucleins Regulate the kinetics of synaptic vesicle endocytosis. J Neurosci2014;
34:9364–76
252.
DuceJAWongBXDurhamHDevedjianJ-CSmithDPDevosD.Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson’s disease. Mol Neurodegener2017;
12:45
253.
OrtegaRCarmonaARoudeauSPerrinLDučićTCarboniEBohicSCloetensPLingorP.α-Synuclein over-Expression induces increased iron accumulation and redistribution in Iron-Exposed neurons. Mol Neurobiol2016;
53:1925–34
254.
AngelovaPRChoiMLBerezhnovAVHorrocksMHHughesCDDeSRodriguesMYapomRLittleDDoltKSKunathTDevineMJGissenPShchepinovMSSylantyevSPavlovEVKlenermanDAbramovAYGandhiS. Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation. Cell Death Differ2020 (in press). doi: 10.1038/s41418-020-0542-z
255.
CaoJChenXJiangLLuBYuanMZhuDZhuHHeQYangBYingM.DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase. Nat Commun2020;
11:15
256.
RothJASingletonSFengJGarrickMParadkarPN.Parkin regulates metal transport via proteasomal degradation of the 1B isoforms of divalent metal transporter 1. J Neurochem2010;
113:454–64
257.
GarrickMDZhaoLRothJAJiangHFengJFootNJDaltonHKumarSGarrickLM.Isoform specific regulation of divalent metal (ion) transporter (DMT1) by proteasomal degradation. Biometals2012;
25:787–93
258.
ZhangC-WTaiYKChaiB-HChewKCMAngE-TTsangFTanBWQHongETEAsadABAChuangK-HLimK-LSoongTW.Transgenic mice overexpressing the divalent metal transporter 1 exhibit iron accumulation and enhanced Parkin expression in the brain. Neuromolecular Med2017;
19:375–86
259.
MoreauCDuceJARascolODevedjianJ-CBergDDexterDCabantchikZIBushAIDevosD.Iron as a therapeutic target for Parkinson’s disease. Mov Disord2018;
33:568–74
260.
DevosDMoreauCDevedjianJCKluzaJPetraultMLalouxCJonneauxARyckewaertGGarçonGRouaixNDuhamelAJissendiPDujardinKAugerFRavasiLHopesLGrolezGFirdausWSablonnièreBStrubi-VuillaumeIZahrNDestéeACorvolJ-CPöltlDLeistMRoseCDefebvreLMarchettiPCabantchikZIBordetR.Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal2014;
21:195–210
261.
DexterDTStattonSAWhitmoreCFreinbichlerWWeinbergerPTiptonKFDella CorteLWardRJCrichtonRR.Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration. J Neural Transm2011;
118:223–31
262.
CarboniETatenhorstLTöngesLBarskiEDambeckVBährMLingorP.Deferiprone rescues behavioral deficits induced by mild iron exposure in a mouse model of alpha-synuclein aggregation. Neuromolecular Med2017;
19:309–21
GrünblattEMandelSGassenMYoudimMB.Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. J Neural Transm Suppl1999;
55:57–70
265.
DasBRajagopalanSJoshiGSXuLLuoDAndersenJKTodiSVDuttaAK.A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo. Neuropharmacology2017;
123:88–99
266.
FinkelsteinDIBillingsJLAdlardPAAytonSSedjahteraAMastersCLWilkinsSShacklefordDMCharmanSABalWZawiszaIAKurowskaEGundlachALMaSBushAIHareDJDoblePACrawfordSGautierECParsonsJHugginsPBarnhamKJChernyRA.The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease. Acta Neuropathol Commun2017;
5:53
267.
FinkelsteinDIHareDJBillingsJLSedjahteraANurjonoMArthoferEGeorgeSCulvenorJGBushAIAdlardPA.Clioquinol improves cognitive, motor function, and microanatomy of the alpha-synuclein hA53T transgenic mice. ACS Chem Neurosci2016;
7:119–29
268.
BillingsJLHareDJNurjonoMVolitakisIChernyRABushAIAdlardPAFinkelsteinDI.Effects of neonatal iron feeding and chronic clioquinol administration on the parkinsonian human A53T transgenic mouse. ACS Chem Neurosci2016;
7:360–6
269.
GotsbacherMPTelferTJWittingPKDoubleKLFinkelsteinDICoddR.Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson’s disease. Metallomics2017;
9:852–64
270.
AguirrePGarcía-BeltránOTapiaVMuñozYCasselsBKNúñezMT.Neuroprotective effect of a new 7,8-dihydroxycoumarin-Based Fe2+/Cu2+ chelator in cell and animal models of Parkinson’s disease. ACS Chem Neurosci2017;
8:178–85
271.
ZhuYWangBTaoKYangHWangYZhouTYangYYuanLLiuXDuanY.Iron accumulation and microglia activation contribute to substantia nigra hyperechogenicity in the 6-OHDA-induced rat model of Parkinson’s disease. Parkinsonism Relat Disord2017;
36:76–82
272.
Martin-BastidaAWardRJNewbouldRPicciniPSharpDKabbaCPatelMCSpinoMConnellyJTrictaFCrichtonRRDexterDT.Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease. Sci Rep2017;
7:1398
273.
GrolezGMoreauCSablonnièreBGarçonGDevedjianJ-CMeguigSGeléPDelmaireCBordetRDefebvreLCabantchikIZDevosD.Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease. BMC Neurol2015;
15:74
274.
MatakPMatakAMoustafaSAryalDKBennerEJWetselWAndrewsNC.Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. Proc Natl Acad Sci U S A2016;
113:3428–35
275.
AytonSZhangMRobertsBRLamLQLindMMcLeanCBushAIFrugierTCrackPJDuceJA.Ceruloplasmin and β-amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron. Free Radic Biol Med2014;
69:331–7
276.
AytonSLeiPDuceJAWongBXWSedjahteraAAdlardPABushAIFinkelsteinDI.Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann Neurol2013;
73:554–9
277.
AytonSLeiPMcleanCBushAIFinkelsteinDI.Transferrin protects against parkinsonian neurotoxicity and is deficient in Parkinson’s substantia nigra. Signal Transduct Target Ther2016;
1:16015
278.
KaurDRajagopalanSChintaSKumarJDi MonteDChernyRAAndersenJK.Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration. Brain Res2007;
1140:188–94
279.
LiangTQianZ-MMuM-DYungW-HKeY.Brain hepcidin suppresses major pathologies in experimental parkinsonism. iScience2020;
23:101284
280.
DuFQianZ-MLuoQYungW-HKeY.Hepcidin suppresses brain iron accumulation by downregulating iron transport proteins in iron-overloaded rats. Mol Neurobiol2015;
52:101–14
281.
ZhouY-FZhangCYangGQianZ-MZhangM-WMaJZhangF-LKeY.Hepcidin protects neuron from hemin-mediated injury by reducing iron. Front Physiol2017;
8:332
282.
QianZ-MKeY.Hepcidin and its therapeutic potential in neurodegenerative disorders. Med Res Rev2019;
40:633–53
283.
VelaD.The dual role of hepcidin in brain iron load and inflammation. Front Neurosci2018;
12:740
284.
SharmaAKaurPKumarVGillKD.Attenuation of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine induced nigrostriatal toxicity in mice by N-acetyl cysteine. Cell Mol Biol2007;
53:48–55
285.
PerryTLYongVWClavierRMJonesKWrightJMFoulksJGWallRA.Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett1985;
60:109–14
286.
OffenDZivISterninHMelamedEHochmanA.Prevention of Dopamine-Induced cell death by thiol antioxidants: possible implications for treatment of Parkinson’s disease. Exp Neurol1996;
141:32–9
287.
Martínez-BanaclochaMA.N-acetyl-cysteine in the treatment of Parkinson’s disease. What are we waiting for?Med Hypoth2012;
79:8–12
288.
MontiDAZabreckyGKremensDLiangT-WWinteringNABazzanAJZhongLBowensBKChervonevaIIntenzoCNewbergAB.N-Acetyl cysteine is associated with dopaminergic improvement in Parkinson’s disease. Clin Pharmacol Ther2019;
106:884–90
289.
SelkoeDMandelkowEHoltzmanD.Deciphering Alzheimer disease. Cold Spring Harb Perspect Med2012;
2:a011460
290.
SelkoeDJHardyJ.The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med2016;
8:595–608
291.
HoltzmanDMMandelkowESelkoeDJ.Alzheimer disease in 2020. Cold Spring Harb Perspect Med2012;2:a011585
292.
IqbalKLiuFGongC-X.Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles. Biochem Pharmacol2014;
88:631–9
293.
ReissABArainHASteckerMMSiegartNMKasselmanLJ.Amyloid toxicity in Alzheimer’s disease. Rev Neurosci2018;
29:613–27
294.
ChenX-QMobleyWC.Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric Aβ and tau species. Front Neurosci2019;
13:659
295.
GuerreiroRHardyJ.Genetics of Alzheimer’s disease. Neurotherapeutics2014;
11:732–7
296.
ChourakiVSeshadriS.Genetics of Alzheimer’s disease. Adv Genet2014;
87:245–94
297.
WolfeCMFitzNFNamKNLefterovIKoldamovaR.The role of APOE and TREM2 in Alzheimer’s disease-current understanding and perspectives. Int J Mol Sci2018;
20:81
298.
LaneDJRAytonSBushAI.Iron and Alzheimer’s disease: an update on emerging mechanisms. J Alzheimers Dis2018;
64:S379–95
299.
MandelSAmitTBar-AmOYoudimMBH.Iron dysregulation in Alzheimer’s disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol2007;
82:348–60
300.
BushAI.The metal theory of Alzheimer’s disease. J Alzheimers Dis2013;
33(Suppl 1):S277–281
301.
PetersDGConnorJRMeadowcroftMD.The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer’s disease: two sides of the same coin. Neurobiol Dis2015;
81:49–65
302.
DingBChenK-MLingH-WSunFLiXWanTChaiW-MZhangHZhanYGuanY-J.Correlation of iron in the hippocampus with MMSE in patients with Alzheimer’s disease. J Magn Reson Imaging2009;
29:793–8
303.
RavenEPLuPHTishlerTAHeydariPBartzokisG.Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer’s disease detected in vivo with magnetic resonance imaging. J Alzheimer Dis2013;
37:127–36
304.
BrarSHendersonDSchenckJZimmermanEA.Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism. Arch Neurol2009;
66:371–4
305.
van BergenJMGLiXQuevencoFCGietlAFTreyerVMeyerRBuckAKaufmannPANitschRMvan ZijlPCMHockCUnschuldPG.Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and β-amyloid as an indicator of cognitive performance at high age. Neuroimage2018;
174:308–16
306.
RahaAAVaishnavRAFriedlandRPBomfordARaha-ChowdhuryR.The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer’s disease. Acta Neuropathol Commun2013;
1:55
307.
van DuijnSBulkMvan DuinenSGNabuursRJAvan BuchemMAvan der WeerdLNattéR.Cortical iron reflects severity of Alzheimer’s disease. J Alzheimer Dis2017;
60:1533–45
308.
AytonSWangYDioufISchneiderJABrockmanJMorrisMCBushAI.Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Mol Psychiatry 2019. doi: 10.1038/s41380-019-0375-7
309.
GongN-JDibbRBulkMvan der WeerdLLiuC.Imaging beta amyloid aggregation and iron accumulation in Alzheimer’s disease using quantitative susceptibility mapping MRI. Neuroimage2019;
191:176–85
310.
DuLZhaoZCuiAZhuYZhangLLiuJShiSFuCHanXGaoWSongTXieLWangLSunSGuoRMaG.Increased iron deposition on brain quantitative susceptibility mapping correlates with decreased cognitive function in Alzheimer’s disease. ACS Chem Neurosci2018;
9:1849–57
311.
BulkMAbdelmoulaWMNabuursRJAvan der GraafLMMuldersCWHMulderAAJostCRKosterAJvan BuchemMANattéRDijkstraJvan der WeerdL.Postmortem MRI and histology demonstrate differential iron accumulation and cortical myelin organization in early- and late-onset Alzheimer’s disease. Neurobiol Aging2018;
62:231–42
312.
KenkhuisBJonkmanLEBulkMBuijsMBoonBDCBouwmanFHGeurtsJJGvan de BergWDJvan der WeerdL.7T MRI allows detection of disturbed cortical lamination of the medial temporal lobe in patients with Alzheimer’s disease. Neuroimage Clin2019;
21:101665
313.
DioufIFazlollahiABushAIAytonS, Alzheimer’s disease Neuroimaging Initiative.
Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying β-amyloid pathology. Neurobiol Dis2019;
124:335–9
314.
AytonSDioufIBushAI, Alzheimer’s disease Neuroimaging Initiative.
Evidence that iron accelerates Alzheimer’s pathology: a CSF biomarker study. J Neurol Neurosurg Psychiatry2018;
89:456–60
315.
AytonSFauxNGBushAI.Association of cerebrospinal fluid ferritin level with preclinical cognitive decline in APOE-ε4 carriers. JAMA Neurol2017;
74:122–5
316.
AytonSFauxNGBushAI, Alzheimer’s Disease Neuroimaging Initiative.
Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE. Nat Commun2015;
6:6760
317.
KagererSMvan BergenJMGLiXQuevencoFCGietlAFStuderSTreyerVMeyerRKaufmannPANitschRMvan ZijlPCMHockCUnschuldPG.APOE4 moderates effects of cortical iron on synchronized default mode network activity in cognitively healthy old-aged adults. Alzheimers Dement2020;
12:e12002
318.
LiXLeiPTuoQAytonSLiQ-XMoonSVolitakisILiuRMastersCLFinkelsteinDIBushAI.Enduring elevations of hippocampal amyloid precursor protein and iron are features of β-Amyloid toxicity and are mediated by tau. Neurotherapeutics2015;
12:862–73
319.
GerhardssonLLundhTLondosEMinthonL.Cerebrospinal fluid/plasma quotients of essential and non-essential metals in patients with Alzheimer’s disease. J Neural Transm2011;
118:957–62
320.
GerhardssonLBlennowKLundhTLondosEMinthonL.Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord2009;
28:88–94
321.
HozumiIHasegawaTHondaAOzawaKHayashiYHashimotoKYamadaMKoumuraASakuraiTKimuraATanakaYSatohMInuzukaT.Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J Neurol Sci2011;
303:95–9
322.
LavadosMGuillónMMujicaMCRojoLEFuentesPMaccioniRB.Mild cognitive impairment and alzheimer patients display different levels of redox-active CSF iron. J Alzheimers Dis2008;
13:225–32
323.
MolinaJAJiménez-JiménezFJAguilarMVMeseguerIMateos-VegaCJGonzález-MuñozMJde BustosFPortaJOrtí-ParejaMZurdoMBarriosEMartínez-ParaMC.Cerebrospinal fluid levels of transition metals in patients with Alzheimer’s disease. J Neural Transm1998;
105:479–88
324.
DioufIBushAIAytonS, Alzheimer’s disease Neuroimaging Initiative.
Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying β-amyloid pathology. Neurobiol Dis2020;
139:104810
325.
RogersJTRandallJDCahillCMEderPSHuangXGunshinHLeiterLMcPheeJSarangSSUtsukiTGreigNHLahiriDKTanziREBushAIGiordanoTGullansSR.An iron-responsive element type II in the 5’-untranslated region of the Alzheimer’s amyloid precursor protein transcript. J Biol Chem2002;
277:45518–28
326.
GreenoughMACamakarisJBushAI.Metal dyshomeostasis and oxidative stress in Alzheimer’s disease. Neurochem Int2013;
62:540–55
327.
BelaidiAAGunnAPWongBXAytonSAppukuttanATRobertsBRDuceJABushAI.Marked age-related changes in brain iron homeostasis in amyloid protein precursor knockout mice. Neurotherapeutics2018;
15:1055–62
328.
DuceJATsatsanisACaterMAJamesSARobbEWikheKLeongSLPerezKJohanssenTGreenoughMAChoH-HGalatisDMoirRDMastersCLMcLeanCTanziRECappaiRBarnhamKJCiccotostoGDRogersJTBushAI.Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell2010;
142:857–67
329.
McCarthyRCParkY-HKosmanDJ.sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. EMBO Rep2014;
15:809–15
330.
LahiriDKMaloneyBWangR.APPealing for a role in cellular iron efflux. J Biol Chem2019;
294:9365
331.
Xian-HuiDWei-JuanGTie-MeiSHong-LinXJiang-TaoBJing-YiZXi-QingC.Age-related changes of brain iron load changes in the frontal cortex in APPswe/PS1ΔE9 transgenic mouse model of Alzheimer’s disease. J Trace Elem Med Biol2015;
30:118–23
332.
TsatsanisADickensSKwokJCFWongBXDuceJA.Post translational modulation of β-amyloid precursor protein trafficking to the cell surface alters neuronal iron homeostasis. Neurochem Res2019;
44:1367–74
TsatsanisAWongBXGunnAPAytonSBushAIDevosDDuceJA.Amyloidogenic processing of Alzheimer’s disease β-amyloid precursor protein induces cellular iron retention. Mol Psychiatry2020. doi: 10.1038/s41380-020-0762-0
335.
DekensDWDe DeynPPSapFEiselULMNaudéPJW.Iron chelators inhibit amyloid-β-induced production of lipocalin 2 in cultured astrocytes. Neurochem Int2020;
132:104607
336.
VerkhratskyAParpuraVRodriguez-ArellanoJJZorecR.Astroglia in Alzheimer’s disease. Adv Exp Med Biol2019;
1175:273–324
337.
Trujillo-EstradaLGomez-ArboledasAFornerSMartiniACGutierrezABaglietto-VargasDLaFerlaFM.Astrocytes: from the physiology to the disease. Curr Alzheimer Res2019;
16:675–98
338.
LiangZVallaJSefidvash‐HockleySRogersJLiR.Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer’s disease patients. J Neurochem2002;
80:807–14
339.
McIntoshAMelaVHartyCMinogueAMCostelloDAKerskensCLynchMA.Iron accumulation in microglia triggers a Cascade of events that leads to altered metabolism and compromised function in APP/PS1 mice. Brain Pathol2019;
29:606–21
340.
TiepoltSSchäferARullmannMRoggenhoferENetherlands Brain Bank GertzH-JSchroeterMLPattMBazinP-LJochimsenTHTurnerRSabriOBarthelH.Quantitative susceptibility mapping of amyloid-β aggregates in Alzheimer’s disease with 7T MR. J Alzheimer Dis2018;
64:393–404
341.
UrrutiaPJHirschECGonzález-BillaultCNúñezMT.Hepcidin attenuates amyloid beta-induced inflammatory and pro-oxidant responses in astrocytes and microglia. J Neurochem2017;
142:140–52
342.
AhmadiSWuBSongRZhuSSimpsonAWilsonDJKraatzH-B.Exploring the interactions of iron and zinc with the microtubule binding repeats R1 and R4. J Inorg Biochem2019;
205:110987
343.
AhmadiSZhuSSharmaRWilsonDJKraatzH-B.Interaction of metal ions with tau protein. The case for a metal-mediated tau aggregation. J Inorg Biochem2019;
194:44–51
344.
EverettJCéspedesEShelfordLRExleyCCollingwoodJFDobsonJvan der LaanGJenkinsCAArenholzETellingND.Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer’s disease peptide β-amyloid (1-42). J R Soc Interface2014;
11:20140165
345.
KimACLimSKimYK.Metal ion effects on Aβ and tau aggregation. Int J Mol Sci2018;
19:128
346.
TellingNDEverettJCollingwoodJFDobsonJvan der LaanGGallagherJJWangJHitchcockAP.Iron biochemistry is correlated with amyloid plaque morphology in an established mouse model of Alzheimer’s disease. Cell Chem Biol2017;
24:1205–15.e3
347.
YamamotoAShinR-WHasegawaKNaikiHSatoHYoshimasuFKitamotoT.Iron (III) induces aggregation of hyperphosphorylated τ and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer’s disease. J Neurochem2002;
82:1137–47
348.
GoodPFPerlDPBiererLMSchmeidlerJ.Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer’s disease: a laser microprobe (LAMMA) study. Ann Neurol1992;
31:286–92
349.
MeadowcroftMDConnorJRSmithMBYangQX.MRI and histological analysis of beta-amyloid plaques in both human Alzheimer’s disease and APP/PS1 transgenic mice. J Magn Reson Imaging2009;
29:997–1007
350.
SmithMAHarrisPLSayreLMPerryG.Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A1997;
94:9866–8
351.
Plascencia-VillaGPonceACollingwoodJFArellano-JiménezMJZhuXRogersJTBetancourtIJosé-YacamánMPerryG.High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer’s disease. Sci Rep2016;
6:24873
352.
van BergenJMGLiXHuaJSchreinerSJSteiningerSCQuevencoFCWyssMGietlAFTreyerVLehSEBuckFNitschRMPruessmannKPvan ZijlPCMHockCUnschuldPG.Colocalization of cerebral iron with.Sci Rep2016;
6:35514
353.
RottkampCARainaAKZhuXGaierEBushAIAtwoodCSChevionMPerryGSmithMA.Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med2001;
30:447–50
354.
BaderBNüblingGMehleANobileSKretzschmarHGieseA.Single particle analysis of tau oligomer formation induced by metal ions and organic solvents. Biochem Biophys Res Commun2011;
411:190–6
355.
GalanteDCavalloEPericoA, DC.Effect of ferric citrate on amyloid-beta peptides behavior. Biopolymers2018;
109:e23224
356.
SoedaYYoshikawaMAlmeidaOFXSumiokaAMaedaSOsadaHKondohYSaitoAMiyasakaTKimuraTSuzukiMKoyamaHYoshiikeYSugimotoHIharaYTakashimaA.Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. Nat Commun2015;
6:10216
357.
SaharaNMaedaSMurayamaMSuzukiTDohmaeNYenS-HTakashimaA.Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur J Neurosci2007;
25:3020–9
358.
RaoSSAdlardPA.Untangling tau and iron: exploring the interaction between iron and tau in neurodegeneration. Front Mol Neurosci2018;
11:276
359.
WanWCaoLKalionisBMurthiPXiaSGuanY.Iron deposition leads to hyperphosphorylation of tau and disruption of insulin signaling. Front Neurol2019;
10:607
360.
LeiPAytonSFinkelsteinDISpoerriLCiccotostoGDWrightDKWongBXWAdlardPAChernyRALamLQRobertsBRVolitakisIEganGFMcLeanCACappaiRDuceJABushAI.Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med2012;
18:291–5
361.
BaloyannisSJ.Mitochondrial alterations in Alzheimer’s disease. J Alzheimers Dis2006;
9:119–26
362.
HoferTPerryG.Nucleic acid oxidative damage in Alzheimer’s disease-explained by the hepcidin-ferroportin neuronal iron overload hypothesis?J Trace Elem Med Biol2016;
38:1–9
363.
PraticòD.Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal. Trends Pharmacol Sci2008;
29:609–15
364.
Peña-BautistaCTirleTLópez-NoguerolesMVentoMBaqueroMCháfer-PericásC.Oxidative damage of DNA as early marker of Alzheimer’s disease. Int J Mol Sci2019;
20:6136
365.
BalejcikovaLSiposovaKKopcanskyPSafarikI.Fe(II) formation after interaction of the amyloid β-peptide with iron-storage protein ferritin. J Biol Phys2018;
44:237–43
366.
EverettJBrooksJLermyteFO’ConnorPBSadlerPJDobsonJCollingwoodJFTellingND.Iron stored in ferritin is chemically reduced in the presence of aggregating Aβ(1-42). Sci Rep2020;
10:10332
367.
EverettJCéspedesEShelfordLRExleyCCollingwoodJFDobsonJvan der LaanGJenkinsCAArenholzETellingND.Evidence of redox-active iron formation following aggregation of ferrihydrite and the Alzheimer’s disease peptide β-amyloid. Inorg Chem2014;
53:2803–9
368.
MerloDMollinariCRacanielloMGaraciECardinaleA.DNA double strand breaks: a common theme in neurodegenerative diseases. Curr Alzheimer Res2016;
13:1208–18
369.
ShichiriM.The role of lipid peroxidation in neurological disorders. J Clin Biochem Nutr2014;
54:151–60
370.
DerryPJHegdeMLJacksonGRKayedRTourJMTsaiA-LKentTA.Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective. Prog Neurobiol2020;
184:101716
371.
CongLDongXWangYDengYLiBDaiR.On the role of synthesized hydroxylated chalcones as dual functional amyloid-β aggregation and ferroptosis inhibitors for potential treatment of Alzheimer’s disease. Eur J Med Chem2019;
166:11–21
372.
WeilandAWangYWuWLanXHanXLiQWangJ.Ferroptosis and its role in diverse brain diseases. Mol Neurobiol2019;
56:4880–93
373.
YanNZhangJ.Iron metabolism, ferroptosis, and the links with Alzheimer’s disease. Front Neurosci2019;
13:1443
374.
AshrafAJeandriensJParkesHGSoP-W.Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer’s disease: evidence of ferroptosis. Redox Biol2020;
32:101494
375.
ButtAMDe La RochaICRiveraA.Oligodendroglial cells in Alzheimer’s disease. Adv Exp Med Biol2019;
1175:325–33
376.
TseK-HHerrupK.DNA damage in the oligodendrocyte lineage and its role in brain aging. Mech Ageing Dev2017;
161:37–50
377.
TseK-HChengAMaFHerrupK.DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer’s disease and dementia. Alzheimers Dement2018;
14:664–79
378.
KellDBPretoriusE.No effects without causes: the iron dysregulation and dormant microbes hypothesis for chronic, inflammatory diseases. Biol Rev Camb Philos Soc2018;
93:1518–57
379.
PretoriusEBesterJKellDB.A bacterial component to Alzheimer’s-Type dementia seen via a systems biology approach that links iron dysregulation and inflammagen shedding to disease. J Alzheimers Dis2016;
53:1237–56
380.
PretoriusLKellDBPretoriusE.Iron dysregulation and dormant microbes as causative agents for impaired blood rheology and pathological clotting in Alzheimer’s type dementia. Front Neurosci2018;
12:851
381.
AdamsBNunesJMPageMJRobertsTCarrJNellTAKellDBPretoriusE.Parkinson’s disease: a systemic inflammatory disease accompanied by bacterial inflammagens. Front Aging Neurosci2019;
11:210
KellDBPretoriusE.Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics2014;
6:748–73
384.
AdlardPABushAI.Metal chaperones: a holistic approach to the treatment of Alzheimer’s disease. Front Psychiatry2012;
3:15
385.
BudimirA.Metal ions, Alzheimer’s disease and chelation therapy. Acta Pharm2011;
61:1–14
386.
TahmasebiniaFEmadiS.Effect of metal chelators on the aggregation of beta-amyloid peptides in the presence of copper and iron. Biometals2017;
30:285–93
387.
MurayamaHShinRWHiguchiJShibuyaSMuramotoTKitamotoT.Interaction of aluminum with PHFtau in Alzheimer’s disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method. Am J Pathol1999;
155:877–85
388.
ShinR-WKruckTPAMurayamaHKitamotoT.A novel trivalent cation chelator feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer’s disease. Brain Res2003;
961:139–46
389.
FineJMRennerDBForsbergACCameronRAGalickBTLeCConwayPMStroebelBMFreyWHHansonLR.Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation. Neurosci Lett2015;
584:362–7
390.
GuoCWangPZhongM-LWangTHuangX-SLiJ-YWangZ-Y.Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem Int2013;
62:165–72
391.
GuoCWangTZhengWShanZ-YTengW-PWangZ-Y.Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer’s disease. Neurobiol Aging2013;
34:562–75
392.
FineJMBaillargeonAMRennerDBHoersterNSTokarevJColtonSPellegAAndrewsASparleyKAKroghKMFreyWHHansonLR.Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice. Exp Brain Res2012;
219:381–90
393.
ZhangYHeM-L.Deferoxamine enhances alternative activation of microglia and inhibits amyloid beta deposits in APP/PS1 mice. Brain Res2017;
1677:86–92
394.
Salkovic-PetrisicMKnezovicAOsmanovic-BarilarJSmailovicUTrkuljaVRiedererPAmitTMandelSYoudimMBH.Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer’s disease. Life Sci2015;
136:108–19
395.
RivalTPageRMChandraratnaDSSendallTJRyderELiuBLewisHRosahlTHiderRCamargoLMShearmanMSCrowtherDCLomasDA.Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a drosophila model of Alzheimer’s disease. Eur J Neurosci2009;
29:1335–47
396.
C, McLachlanDRDaltonAJKruckTPBellMYSmithWLKalowWAndrewsDF.Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet1991;
337:1304–8
397.
RitchieCWBushAIMackinnonAMacfarlaneSMastwykMMacGregorLKiersLChernyRLiQ-XTammerACarringtonDMavrosCVolitakisIXilinasMAmesDDavisSBeyreutherKTanziREMastersCL.Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol2003;
60:1685–91
398.
LannfeltLBlennowKZetterbergHBatsmanSAmesDHarrisonJMastersCLTargumSBushAIMurdochRWilsonJRitchieCW.PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting abeta as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol2008;
7:779–86
399.
HuangJChenSHuLNiuHSunQLiWTanGLiJJinLLyuJZhouH.Mitoferrin-1 is involved in the progression of Alzheimer’s disease through targeting mitochondrial iron metabolism in a Caenorhabditis elegans model of Alzheimer’s disease. Neuroscience2018;
385:90–101
400.
LeviSTirantiV.Neurodegeneration with brain iron accumulation disorders: valuable models aimed at understanding the pathogenesis of iron deposition. Pharmaceuticals2019;
12:27
401.
LeviSCozziASantambrogioP.Iron pathophysiology in neurodegeneration with brain iron accumulation. Adv Exp Med Biol2019;
1173:153–77
402.
HayflickSJKurianMAHogarthP.Neurodegeneration with brain iron accumulation. Handb Clin Neurol2018;
147:293–305
403.
WangZ-BLiuJ-YXuX-JMaoX-YZhangWZhouH-HLiuZ-Q.Neurodegeneration with brain iron accumulation: insights into the mitochondria dysregulation. Biomed Pharmacother2019;
118:109068
404.
CostainGGhoshMCMaioNCarnevaleASiYCRouaultTAYoonG.Absence of iron-responsive element-binding protein 2 causes a novel neurodegenerative syndrome. Brain2019;
142:1195–202
405.
MarchiGBustiFZidanesLACastagnaAGirelliD.Aceruloplasminemia: a severe neurodegenerative disorder deserving an early diagnosis. Front Neurosci2019;
13:325
406.
PipernoAAlessioM.Aceruloplasminemia: waiting for an efficient therapy. Front Neurosci2018;
12:903
407.
PelucchiSMarianiRRavasiGPelloniIMaranoMTremolizzoLAlessioMPipernoA.Phenotypic heterogeneity in seven italian cases of aceruloplasminemia. Parkinsonism Relat Disord2018;
51:36–42
408.
KonoS.Aceruloplasminemia: an update. Int Rev Neurobiol2013;
110:125–51
409.
KonoS.Aceruloplasminemia. Curr Drug Targets2012;
13:1190–9
410.
KonoSYoshidaKTomosugiNTeradaTHamayaYKanaokaSMiyajimaH.Biological effects of mutant ceruloplasmin on hepcidin-mediated internalization of ferroportin. Biochim Biophys Acta2010;
1802:968–75
411.
ZanardiAContiACremonesiMD’AdamoPGilbertiEApostoliPCannistraciCVPipernoADavidSAlessioM.Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia. EMBO Mol Med2018;
10:91–106
412.
KanekoKYoshidaKArimaKOharaSMiyajimaHKatoTOhtaMIkedaS.Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia. J Neuropathol Exp Neurol2002;
61:1069–77
413.
OideTYoshidaKKanekoKOhtaMArimaK.Iron overload and antioxidative role of perivascular astrocytes in aceruloplasminemia. Neuropathol Appl Neurobiol2006;
32:170–6
414.
KanekoKHinenoAYoshidaKOharaSMoritaHIkedaS.Extensive brain pathology in a patient with aceruloplasminemia with a prolonged duration of illness. Hum Pathol2012;
43:451–6
415.
BreuerWHershkoCCabantchikZI.The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci2000;
23:185–92
416.
WangBWangX-P.Does ceruloplasmin defend against neurodegenerative diseases?Curr Neuropharmacol2019;
17:539–49
417.
RyanFZarrukJGLößleinLDavidS.Ceruloplasmin plays a neuroprotective role in cerebral ischemia. Front Neurosci2018;
12:988
418.
ZhaoY-SZhangL-HYuP-PGouY-JZhaoJYouL-HWangZ-YZhengXYanL-JYuPChangY-Z.Ceruloplasmin, a potential therapeutic agent for Alzheimer’s disease. Antioxid Redox Signal2018;
28:1323–37
419.
HinenoAKanekoKYoshidaKIkedaS.Ceruloplasmin protects against rotenone-induced oxidative stress and neurotoxicity. Neurochem Res2011;
36:2127–35
ShinE-JJeongJHChungCKKimD-JWieM-BParkESChungYHNamYTranT-VLeeSYKimH-JOngW-YKimH-C.Ceruloplasmin is an endogenous protectant against kainate neurotoxicity. Free Radic Biol Med2015;
84:355–72
422.
InoueKAkaikeTMiyamotoYOkamotoTSawaTOtagiriMSuzukiSYoshimuraTMaedaH.Nitrosothiol formation catalyzed by ceruloplasmin. Implication for cytoprotective mechanism in vivo. J Biol Chem1999;
274:27069–75
423.
BoeroLCunibertiLMagnaniNManavelaMYapurVBustosMGómez RossoLMeroñoTMarzialiLVialeLEvelsonPNegriGBritesF.Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly. Clin Endocrinol2010;
72:654–60
424.
di PattiMCBMaioNRizzoGDe FrancescoGPersichiniTColasantiMPolticelliFMusciG.Dominant mutants of ceruloplasmin impair the copper loading machinery in aceruloplasminemia. J Biol Chem2009;
284:4545–54
425.
HarrisZLDurleyAPManTKGitlinJD.Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci U S A1999;
96:10812–7
426.
JeongSYDavidS.Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J Neurosci2006;
26:9810–9
427.
VroegindeweijLHPBoonAJWWilsonJHPLangendonkJG.Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports. Orphanet J Rare Dis2020;
15:105
428.
YonekawaMOkabeTAsamotoYOhtaM.A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma. Eur Neurol1999;
42:157–62
429.
PoliLAlbericiABuzziPMarchinaELanariAArosioCCicconeASemeraroFGasparottiRPadovaniABorroniB.Is aceruloplasminemia treatable? Combining iron chelation and fresh-frozen plasma treatment. Neurol Sci2017;
38:357–60
430.
CurtisARFeyCMorrisCMBindoffLAIncePGChinneryPFCoulthardAJacksonMJJacksonAPMcHaleDPHayDBarkerWAMarkhamAFBatesDCurtisABurnJ.Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet2001;
28:350–4
431.
LuscietiSSantambrogioPLanglois d’EstaintotBGranierTCozziAPoliMGalloisBFinazziDCattaneoALeviSArosioP.Mutant ferritin L-chains that cause neurodegeneration act in a dominant-negative manner to reduce ferritin iron incorporation. J Biol Chem2010;
285:11948–57
432.
McNallyJRMehlenbacherMRLuscietiSSmithGLReutovichAAMauraPArosioP.Bou-Abdallah F. Mutant L-chain ferritins that cause neuroferritinopathy alter ferritin functionality and iron permeability. Metallomics2019;
11:1635–47
433.
ChinneryPFCromptonDEBirchallDJacksonMJCoulthardALombèsAQuinnNWillsAFletcherNMottersheadJPCooperPKellettMBatesDBurnJ.Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain2007;
130:110–9
434.
DevosDTchofoPJVuillaumeIDestéeABateySBurnJChinneryPF.Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation. Brain2009;
132:e109
435.
MancusoMDavidzonGKurlanRMTawilRBonillaEDi MauroSPowersJM.Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol2005;
64:280–94
436.
KumarNRizekPJogM.Neuroferritinopathy: pathophysiology, presentation, differential diagnoses and management. Tremor Other Hyperkinet Mov2016;
6:355
437.
MaccarinelliFPaganiACozziACodazziFDi GiacomoGCapocciaSRapinoSFinazziDPolitiLSCirulliFGiorgioMCremonaOGrohovazFLeviS.A novel neuroferritinopathy mouse model (FTL 498InsTC) shows progressive brain iron dysregulation, morphological signs of early neurodegeneration and motor coordination deficits. Neurobiol Dis2015;
81:119–33
438.
BaraibarMAMuhoberacBBGarringerHJHurleyTDVidalR.Unraveling of the E-helices and disruption of 4-fold pores are associated with iron mishandling in a mutant ferritin causing neurodegeneration. J Biol Chem2010;
285:1950–6
439.
BaraibarMABarbeitoAGMuhoberacBBVidalR.A mutant light-chain ferritin that causes neurodegeneration has enhanced propensity toward oxidative damage. Free Radic Biol Med2012;
52:1692–7
440.
CozziARovelliEFrizzaleGCampanellaAAmendolaMArosioPLeviS.Oxidative stress and cell death in cells expressing L-ferritin variants causing neuroferritinopathy. Neurobiol Dis2010;
37:77–85
441.
CozziASantambrogioPCorsiBCampanellaAArosioPLeviS.Characterization of the l-ferritin variant 460InsA responsible of a hereditary ferritinopathy disorder. Neurobiol Dis2006;
23:644–52
442.
VidalRMiravalleLGaoXBarbeitoAGBaraibarMAHekmatyarSKWidelMBansalNDelisleMBGhettiB.Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice. J Neurosci2008;
28:60–7
443.
CapocciaSMaccarinelliFBuffoliBRodellaLFCremonaOArosioPCirulliF.Behavioral characterization of mouse models of neuroferritinopathy. PLoS One2015;
10:e0118990
444.
GarringerHJIrimiaJMLiWGoodwinCBRichineBActonAChanRJPeacockMMuhoberacBBGhettiBVidalR.Effect of systemic iron overload and a chelation therapy in a mouse model of the neurodegenerative disease hereditary ferritinopathy. PLoS One2016;
11:e0161341
445.
CozziAOrellanaDISantambrogioPRubioACancellieriCGiannelliSRipamontiMTavernaSDi LulloGRovidaEFerrariMForniGLFiorilloCBroccoliVLeviS.Stem cell modeling of neuroferritinopathy reveals iron as a determinant of senescence and ferroptosis during neuronal aging. Stem Cell Rep2019;
13:832–46
446.
ZhouBWestawaySKLevinsonBJohnsonMAGitschierJHayflickSJ.A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet2001;
28:345–9
447.
HartigMBProkischHMeitingerTKlopstockT.Pantothenate kinase-associated neurodegeneration. Curr Drug Targets2012;
13:1182–9
448.
HartigMBHörtnagelKGaravagliaBZorziGKmiecTKlopstockTRostasyKSvetelMKosticVSSchuelkeMBotzEWeindlANovakovicINardocciNProkischHMeitingerT.Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol2006;
59:248–56
449.
JohnsonMAKuoYMWestawaySKParkerSMChingKHLGitschierJHayflickSJ.Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann N Y Acad Sci2004;
1012:282–98
450.
KruerMCHikenMGregoryAMalandriniAClarkDHogarthPGrafeMHayflickSJWoltjerRL.Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain2011;
134:947–58
451.
LiAPaudelRJohnsonRCourtneyRLeesAJHoltonJLHardyJReveszTHouldenH.Pantothenate kinase-associated neurodegeneration is not a synucleinopathy. Neuropathol Appl Neurobiol2013;
39:121–31
452.
SantambrogioPRipamontiMPaolizziCPanteghiniCCarecchioMChiappariniLRaimondiMRubioADi MeoICozziATavernaSDe PalmaGTirantiVLeviS.Harmful Iron-Calcium relationship in pantothenate kinase associated neurodegeneration. Int J Mol Sci2020;
21:3664
453.
KuoY-MDuncanJLWestawaySKYangHNuneGXuEYHayflickSJGitschierJ.Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia. Hum Mol Genet2005;
14:49–57
454.
BrunettiDDusiSMorbinMUggettiAModaFD’AmatoIGiordanoCd’AmatiGCozziALeviSHayflickSTirantiV.Pantothenate kinase-associated neurodegeneration: altered mitochondria membrane potential and defective respiration in Pank2 knock-out mouse model. Hum Mol Genet2012;
21:5294–305
455.
BrunettiDDusiSGiordanoCLampertiCMorbinMFugnanesiVMarchetSFagiolariGSibonOMoggioMd’AmatiGTirantiV.Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model. Brain2014;
137:57–68
456.
SubramanianCYaoJFrankMWRockCOJackowskiS.A pantothenate kinase-deficient mouse model reveals a gene expression program associated with brain coenzyme a reduction. Biochim Biophys Acta Mol Basis Dis2020;
1866:165663
457.
JeongSYHogarthPPlaczekAGregoryAMFoxRZhenDHamadaJvan der ZwaagMLambrechtsRJinHNilsenACobbJPhamTGrayNRalleMDuffyMSchwanemannLRaiPFreedAWakemanKWoltjerRLSibonOCHayflickSJ.EMBO Mol Med2019;
11:e10489
458.
RanaASeinenESiudejaKMuntendamRSrinivasanBvan der WantJJHayflickSReijngoudD-JKayserOSibonOCM.Pantethine rescues a drosophila model for pantothenate kinase-associated neurodegeneration. Proc Natl Acad Sci U S A2010;
107:6988–93
459.
WuZLiCLvSZhouB.Pantothenate kinase-associated neurodegeneration: insights from a drosophila model. Hum Mol Genet2009;
18:3659–72
460.
ZizioliDTisoNGuglielmiASaracenoCBusolinGGiulianiRKhatriDMontiEBorsaniGArgentonFFinazziD.Knock-down of pantothenate kinase 2 severely affects the development of the nervous and vascular system in zebrafish, providing new insights into PKAN disease. Neurobiol Dis2016;
85:35–48
461.
OrellanaDISantambrogioPRubioAYekhlefLCancellieriCDusiSGiannelliSGVencoPMazzaraPGCozziAFerrariMGaravagliaBTavernaSTirantiVBroccoliVLeviS.Coenzyme a corrects pathological defects in human neurons of PANK2-associated neurodegeneration. EMBO Mol Med2016;
8:1197–211
462.
KlopstockTTrictaFNeumayrLKarinIZorziGFradetteCKmiećTBüchnerBSteeleHEHorvathRChinneryPFBasuAKüpperCNeuhoferCKálmánBDušekPYapiciZWilsonIZhaoFZibordiFNardocciNAguilarCHayflickSJSpinoMBlamireAMHogarthPVichinskyE.Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol2019;
18:631–42
463.
RohaniMRazmehSShahidiGAAlizadehEOroojiM.A pilot trial of deferiprone in pantothenate kinase-associated neurodegeneration patients. Neurol Int2017;
9:7279
464.
HueblJSchneiderSA.Iron chelation in pantothenate kinase-associated neurodegeneration: a possible new avenue for slowing down disease progression in neurodegeneration. Mov Disord2019;
34:1476–7
GuoY-PTangB-SGuoJ-F.PLA2G6-associated neurodegeneration (PLAN): review of clinical phenotypes and genotypes. Front Neurol2018;
9:1100
467.
DarlingAAguilera-AlbesaSTelloCASerranoMTomásMCamino-LeónRFernández-RamosJJiménez-EscrigAPoóPO’CallaghanMOrtezCNascimentoAFernández MesaqueRCMadrugaMArrabalLRoldanSGómez-MartínHGarridoCTemudoTJou-MuñozCMuchartJHuismanTAGMPorettiALupoVEspinósCPérez-DueñasB.PLA2G6-associated neurodegeneration: new insights into brain abnormalities and disease progression. Parkinsonism Relat Disord2019;
61:179–86
468.
RamanadhamSAliTAshleyJWBoneRNHancockWDLeiX.Calcium-independent phospholipases A2 and their roles in biological processes and diseases. J Lipid Res2015;
56:1643–68
469.
RikuYIkeuchiTYoshinoHMimuroMManoKGotoYHattoriNSobueGYoshidaM.Extensive aggregation of α-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site. Acta Neuropathol Commun2013;
1:12
470.
IodiceASpagnoliCSalernoGGFrattiniDBertaniGBergonziniPPisaniFFuscoC.Infantile neuroaxonal dystrophy and PLA2G6-associated neurodegeneration: an update for the diagnosis. Brain Dev2017;
39:93–100
471.
ChiuC-CWangH-LWengY-HChenR-SChenC-MYehT-HLuC-SChenY-JLiuY-CHuangY-ZChangK-H.Generation of induced pluripotent stem cells from a young-onset Parkinson’s disease patient carrying the compound heterozygous PLA2G6 p.D331Y/p.M358IfsX mutations. Stem Cell Res. 2019;
40:101552
472.
ShenTHuJJiangYZhaoSLinCYinXYanYPuJLaiH-YZhangB.Early-Onset Parkinson’s disease caused by PLA2G6 compound heterozygous mutation. A case report and literature review. Front Neurol2019;
10:915
473.
Sumi-AkamaruHBeckGKatoSMochizukiH.Neuroaxonal dystrophy in PLA2G6 knockout mice. Neuropathology2015;
35:289–302
474.
MalikITurkJMancusoDJMontierLWohltmannMWozniakDFSchmidtREGrossRWKotzbauerPT.Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. Am J Pathol2008;
172:406–16
475.
ShinzawaKSumiHIkawaMMatsuokaYOkabeMSakodaSTsujimotoY.Neuroaxonal dystrophy caused by group via phospholipase A2 deficiency in mice: a model of human neurodegenerative disease. J Neurosci2008;
28:2212–20
476.
WadaHKojoSSeinoK.Mouse models of human INAD by Pla2g6 deficiency. Histol Histopathol2013;
28:965–9
477.
Sumi-AkamaruHBeckGShinzawaKKatoSRikuYYoshidaMFujimuraHTsujimotoYSakodaSMochizukiH.High expression of α-synuclein in damaged mitochondria with PLA2G6 dysfunction. Acta Neuropathol Commun2016;
4:27
478.
IliadiKGGluscencovaOBIliadiNBoulianneGL.Mutations in the drosophila homolog of human PLA2G6 give rise to age-dependent loss of psychomotor activity and neurodegeneration. Sci Rep2018;
8:2939
479.
LinGLeeP-TChenKMaoDTanKLZuoZLinW-WWangLBellenHJ.Phospholipase PLA2G6, a Parkinsonism-associated gene, affects Vps26 and Vps35, retromer function, and ceramide levels, similar to α-synuclein gain. Cell Metab2018;
28:605–18.e6
480.
MorrisonBED’MelloSR.Polydactyly in mice lacking HDAC9/HDRP. Exp Biol Med2008;
233:980–8
481.
WilliamsETChenXMooreDJ.VPS35, the retromer complex and Parkinson’s disease. J Parkinsons Dis2017;
7:219–33
Ansell-SchultzAReyesJFSamuelssonMHallbeckM.Reduced retromer function results in the accumulation of amyloid-beta oligomers. Mol Cell Neurosci2018;
93:18–26
485.
YoungJEFongLKFrankowskiHPetskoGASmallSAGoldsteinLSB.Stabilizing the retromer complex in a human stem cell model of Alzheimer’s disease reduces TAU phosphorylation independently of amyloid precursor protein. Stem Cell Rep2018;
10:1046–58
486.
Sadigh-EteghadSAskari-NejadMSMahmoudiJMajdiA.Cargo trafficking in Alzheimer’s disease: the possible role of retromer. Neurol Sci2016;
37:17–22
487.
TammineniPJeongYYFengTAikalDCaiQ.Impaired axonal retrograde trafficking of the retromer complex augments lysosomal deficits in Alzheimer’s disease neurons. Hum Mol Genet2017;
26:4352–66
488.
ChuJPraticòD.The retromer complex system in a transgenic mouse model of AD: influence of age. Neurobiol Aging2017;
52:32–8
489.
KeMChongC-MZengHHuangMHuangZZhangKCenXLuJ-HYaoXQinDSuH.Azoramide protects iPSC-derived dopaminergic neurons with PLA2G6 D331Y mutation through restoring ER function and CREB signaling. Cell Death Dis2020;
11:130
490.
GuillenC.Azoramide: a new drug for the treatment of type 2 diabetes?Ann Transl Med2016;
4:S45
491.
Rozpędek-KamińskaWSiweckaNWawrzynkiewiczAWojtczakRPytelDDiehlJAMajsterekI.The PERK-Dependent molecular mechanisms as a novel therapeutic target for neurodegenerative diseases. Int J Mol Sci2020;
21:2108
